LEQEMBI Study Reports 76% Lower Advanced AD Progression
LEQEMBI findings cover 560 patients in routine care, with a matched comparison showing slower progression but limits on what the study can establish.
· 3 min read
LEQEMBI findings cover 560 patients in routine care, with a matched comparison showing slower progression but limits on what the study can establish.
· 3 min read
The FDA’s Summit rejection goes beyond survival data, while separate decisions advance GSK and AstraZeneca drugs and Sellas reports a leukemia trial benefit.
· 3 min read
Equity markets continued their positive momentum this week, with major indices posting solid gains following the Federal Reserve's first rate cut of 2025. The main stock market index of United States, the US500, rose to…
Change on the prior close · delayed · as of Nov 18, 2:05 PM ET
Trials, approvals and the deals moving biotech, in your inbox. Free.
Thanks — you're subscribed.